Table 1.
Characteristics of included studies and patients.
| Hor | Registration ID | Year | Study design | cTNM stage | Cis-ineligible or refusal | Study arm(s) | No. of patients | Regimen, cycles | Age (median, years) | Gender (male, %) | Quality |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Kim (28) | KCT0003804 CRIS | 2022 | single-arm | T2-4aN0M0 | No | GC+ Nivolumab | 51 | 3–4 | NA | NA | 14 |
| Van Dijk (29) | NCT03387761cohort I | 2020 | single-arm | T2-T4aN0-1M0, | Regardless | Nivolumab + Ipilimumab | 24 | 3 | 65 | 75% | 15 |
| Goubet (34) | NCT03212651 | 2022 | single-arm | T2-4aN0M0 | NA | Pembrolizumab | 39 | 3 | NA | NA | 12 |
| Necchi (27) | NCT02736266 | 2022 | single-arm | T2-4aN0M0 | Regardless | Pembrolizumab | 114 | 3 | 66 | 86.8% | 15 |
| Szabados (35) | NCT02662309 | 2022 | single-arm | T2–T4aN0M0 | Yes | Atezolizumab | 95 | 2 | 73 | 85% | 15 |
| Koshkin (36) | NCT02451423 | 2021 | single-arm | T2-4aN0-1M0 | Yes | Atezolizumab | 20 | 1-3 | 69 | 75% | 14 |
| Guercio (37) | NCT03520491 | 2022 | non-RCT | T2-4aN0M0, | Yes | armA: Nivolumab | armA:15 | NA | 76 | 80% | 13 |
| armB: Nivolumab + Ipilimumab | armB: 15 | ||||||||||
| Yin (38) | NCT03532451 | 2021 | non-RCT | T2-4aN0-1M0 | Yes | armA: Nivolumab | armA:13 | NA | 75 | 67% | 14 |
| Wei (39) | NCT03773666 | 2020 | single-arm | T2-4aN0M0 | Yes | Durvalumab | 10 | 3 | 67 | 80% | 14 |
| Chanza (40) | NCT03674424 | 2022 | RCT | T2-4aN0-1M0 | armA: No | armA: PG+ Avelumab | armA:28 | 4 | armA: 72 | armA: 93% | 6 |
| armB: Yes | armB: Avelumab | armB: 28 | armB: 75 | armB: 93% | |||||||
| Van Dorp (41) | NCT03387761cohort II | 2021 | single-arm | stage III | Yea | Nivolumab + Ipilimumab | 30 | 3 | NA | NA | 13 |
| Grande (42) | NCT03472274 | 2020 | RCT | cT2‐4aN0-1M0 | No | armA: Durvalumab+Tremelimumab | armA:23 | 3 | NA | NA | 6 |
| armB: GC/ddMVAC | armB: 38 | ||||||||||
| Gao (43) | NCT02812420 | 2020 | single-arm | T2-4aN0M0 | Yes | Durvalumab+ Tremelimumab | 28 | 2 | 71 | 71% | 15 |
| Xing (44) | ChiCTR2000032359 | 2023 | single-arm | T2-4aN0-1M0 | No | GC+ Camrelizumab | 19 | 3 | 69 | 73.7% | 12 |
| Rose (45) | NCT02690558 | 2021 | single-arm | T2-4aN0-1M0 | No | GC+ Pembrolizumab | 39 | 4 | NA | NA | 14 |
| Lin (46) | ChiCTR2000037670 | 2022 | single-arm | T2-4aN0M0 | No | GC+ Tislelizumab | 17 | 4 | 62 | NA | 12 |
| Kaimakliotis (47) | NCT02365766 | 2019 | single-arm | T2-4aN0M0 | No | GC+ Pembrolizumab | 40 | 4 | 65 | 75% | 14 |
| Gupta (48) | NCT03294304 | 2022 | single-arm | T2-4aN0-1M0 | No | GC+ Nivolumab | 41 | 4 | NA | NA | 14 |
| Funt (49) | NCT02989584 | 2021 | single-arm | T2-4aN0M0 | No | GC+ Atezolizumab | 44 | 4 | NA | NA | 12 |
| Cathomas (50) | SAKK 06/17 | 2020 | single-arm | T2-4aN0-1M0 | Yes | GC+ Durvalumab | 61 | 4 | 67.5 | 79% | 14 |
| Thibault (51) | NCT03549715 | 2020 | single-arm | NA | No | ddMVAC+ Durvalumab+Tremelimumab | 12 | 2 | 59.5 | 12 | |
| Hristos (52) | NCT02365766 cohort2 | 2020 | single-arm | T2-4aN0M0 | Yes | Gemcitabine+Pembrolizumab | 37 | 3 | 72 | 70% | 13 |